Last updated: August 17, 2026

Examiner: TRAN, SUSAN T

Tech Center 1600 • Art Units: 1615 1618

This examiner grants 63% of resolved cases

Performance Statistics

62.6%

Allow Rate

+2.6% vs TC avg

1,072

Total Applications

+35.7%

Interview Lift

1153

Avg Prosecution Days

Based on 1028 resolved cases, 2023–2026

0.9%

§101 Eligibility

20.6%

§102 Novelty

41.0%

§103 Obviousness

22.0%

§112 Clarity

App #	Title	Status	Assignee
19270315	PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE	Non-Final OA	ANTECIP BIOVENTURES II LLC
18778708	COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	Non-Final OA	ANTECIP BIOVENTURES II LLC
18019856	SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR	Final Rejection	SK BIOPHARMACEUTICALS CO., LTD.
18008793	ANATABINE POWDER COMPOSITIONS	Final Rejection	PHILIP MORRIS PRODUCTS S.A.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.